

Patient Name:		Date:/	
Patient DOB:			
Nicotine Replacement Therapy Documentation & Communication Form			
Tobacco / Nicotine Use Assessment:	□ Medium o first intake	□ Low □ Other	
□ Previous quit attempts □ Products Intake Comments:	used previously		
Is the patient pregnant or breastfeeding?			
Patient signature if they choose to use NRT:		Date:	
Is the patient < 18 years of age? Yes No If yes, what is the name of the consenting parent or legal guardian?			
Signature of parent or legal guardian		Date:	
Did the patient identify a primary care provider? □ Yes □ No If yes, this communication to the primary care provider must be provided within 72 hours after administration of medication. If no, the patient shall be directed to information describing the benefits of having a primary care provider.			
Tobacco Cessation Therapy Initiated:	Qty	Any Specific Notes/Comments for PCP	
Nicotine patch □ 7 mg, □ 14 mg, □ 21 mg	Nicotine Oral Inhaler	□ 10 mg Cartridge	
Nicotine gum □ 2 mg, □ 4 mg	Nicotine Nasal	□ 0.5mg Spray	
Nicotine lozenge □ 2 mg, □ 4 mg			
□ Provided product instructions per package insert Patch Use Directions: Apply patch to non-hairy, clean, dry skin on upper body between the neck and waist. Remove the previous day's patch before applying new patch. Rotate or switch site where apply patch daily. If you have intense, clear, troubling dreams or you cannot fall asleep only wear patch 16 hours per day with removal at bedtime. Gum Use Directions: Chew gum slowly until it tingles, then park between gum and cheek until tingling stops. Chew again until tingle returns and re-park. Repeat until tingling is gone and discard gum. Do not eat or drink while using gum. Lozenge Use Directions: Dissolve in mouth (do NOT bite). Move around in different places in mouth until taste/tingling stops. Do not eat or drink while using lozenge. Oral Inhaler Directions: Puff gently. Typical use is 5-6 cartridges per day; oral absorption, don't inhale deeply Nasal Spray Directions: Spray 1-2 doses/hour and up to 8-40 doses per day; do not sniff or inhale; tilt head back and spray □ Potential adverse effects, per package insert, reviewed with patient Patch: local skin reactions, headache, sleep disturbances Gum/Lozenge: burning/tingling in mouth, dyspepsia, hypersalivation, hiccups, headache Oral inhaler: mouth/throat irritation, headache, rhinitis, hiccups, dyspepsia Nasal spray: nasal/throat irritation, rhinitis, tearing, sneezing, cough, headache			



Patient Name:		
Patient DOB:		
Follow-up Plan With Patient: □ 1 week □2 weeks □1 month □12 weeks □other	r	
Quit Date Set:		
☐ Provided behavioral support <u>OR</u> referral to 1-800-QUIT NOW program <u>OR</u> other behavioral counseling resource:		
Dhawas sist Names	Pharmacist NPI #:	
Pharmacist Name:	Pharmacist NPI #:	
Pharmacy Address:		
To: [Primary Care Physician]		
From: [Pharmacy / Practice Name]		
[Pharmacy / Practice Address]		
This letter serves to notify you that our shared patient has been dispens	ad nigoting real compart thorony (NDT) nor North	
Carolina NRT Standing Order, which permits immunizing pharmacists or administer NRT. Please see the attached documentation for your rec		
of administer INCL. Flease see the attached documentation for your fec	orus.	
If you have any questions, please call the pharmacy at [pharmacy phon	e #1	
in you have any questions, prouse can the pharmacy at (pharmacy phon	~ "J'	
[Pharmacist Name]		
[Pharmacist NPI #]		